Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SB-705498 + fluticasone propionate
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
SB-705498 + fluticasone propionate is an investigational combination of a selective TRPV1 antagonist (SB-705498) and a synthetic corticosteroid (fluticasone propionate) formulated for intranasal use, primarily evaluated for the treatment of allergic rhinitis. SB-705498 blocks the transient receptor potential vanilloid 1 (TRPV1) ion channel, which is implicated in neurogenic inflammation and pain, while fluticasone propionate acts as a potent glucocorticoid receptor agonist, reducing inflammation. Randomized studies have shown that this combination did not provide additional efficacy over fluticasone propionate alone in allergic rhinitis, despite appropriate target engagement by SB-705498[1][3].
02
Targets
GR (Glucocorticoid receptor)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on SB-705498 + fluticasone propionate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SB-705498 + fluticasone propionate.